Urine protein analysis by gel electrophoresis and laser densitometry after chemotherapy in pediatric cancer patients

Pediatric Hematology and Oncology

Volumn 17, Issue 5, 2000, Pages 365-374

  Mertens, R ^a,b   Granzen, B ^a   Vogt, K ^a   Melzer, H ^a   Mann, H ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Children; Cytostatic treatment; Electrophoresis; Nephrotoxicity; Proteinuria

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; DIAGNOSTIC VALUE; GEL ELECTROPHORESIS; HUMAN; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PROTEIN ANALYSIS; PROTEINURIA; URINALYSIS;

EID: 0033933248     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010050034292     Document Type: Article

References (17)

1. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12:159-165.
2. Brocklebank T, Cooper EH, Richmond K. Sodium dodecyl suphate polyacrylamide gel electrophoresis patterns of proteinuria in various renal diseases of childhood. Pediatr Nephrol. 1991;5:371-375.
3. Boesken OH. SDS-PAGE: Gel Electrophoresis of Urinary Proteins. New York: de Gruyter; 1981.
4. Weber WH. Urinary proteins analysis. J Chromatogr. 1988;429:315-344.
5. Kierdorf H, Melzer H, Mann H, Sieberth HG. Differentation of proteins in polyacylamide gels by a modification of silver staining for the Phast System and a laserdensitometer. Electrophoresis. 1993; 14:820-822.
6. Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr. 1994;153:90-94.
7. Boddy AV, English M, Pearson AD, Idle JR, Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics [see comments]. Eur J Cancer. 1996;7:1179-1184.
8. Berns JS, Haghighat A, Staddon A, et al. Severe, irreversible renal failure after ifosfamide treatment: a clinicopathologic report of two patients. Cancer. 1995;76:497-500.
9. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998;101.
10. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993;11:173-190.
11. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer. 1998;77:1677-1682.
12. Shore R, Greenberg M, Geary D, Koren G. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol. 1992;6:162-165.
13. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer Suppl. 1992;18:S30-S35.
14. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jurgens H. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol. 1994;22:27-32.
15. Friedlaender MM, Haviv YS, Rosenmann E, Peylan-Ramu N. End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy. Am J Nephrol. 1998;18:131-133.
16. Ashraf MS, Skinner R, English MW, Craft AW, Pearson AD. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol. 1997;28:62-64.
17. Brock PR, Koliouskas DE, Barratt M, Yeomans E, Pritchard J. Partial reversibility of cisplatin nephrotoxicity. J Pediatr. 1991;118:531-534.